140 related articles for article (PubMed ID: 38310058)
1. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
[TBL] [Abstract][Full Text] [Related]
3. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
[TBL] [Abstract][Full Text] [Related]
4. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
[TBL] [Abstract][Full Text] [Related]
5. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
[TBL] [Abstract][Full Text] [Related]
6. Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC.
Fan Y; He L; Yang H; Wang Y; Su J; Hou S; Luo Y; Jiang X
J Magn Reson Imaging; 2023 Jun; 57(6):1778-1787. PubMed ID: 36165534
[TBL] [Abstract][Full Text] [Related]
7. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
[TBL] [Abstract][Full Text] [Related]
8. Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface.
Fan Y; Zhao Z; Wang X; Ai H; Yang C; Luo Y; Jiang X
Radiol Med; 2022 Dec; 127(12):1342-1354. PubMed ID: 36284030
[TBL] [Abstract][Full Text] [Related]
9. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
[TBL] [Abstract][Full Text] [Related]
10. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
12. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases.
Xu J; Yang Y; Gao Z; Song T; Ma Y; Yu X; Shi C
Clin Neurol Neurosurg; 2024 May; 240():108258. PubMed ID: 38552362
[TBL] [Abstract][Full Text] [Related]
14. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
15. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.
Lu J; Ji X; Liu X; Jiang Y; Li G; Fang P; Li W; Zuo A; Guo Z; Yang S; Ji Y; Lu D
Sci Rep; 2024 Jan; 14(1):446. PubMed ID: 38172228
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
18. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
Li Y; Lv X; Wang B; Xu Z; Wang Y; Sun M; Hou D
Acad Radiol; 2023 Sep; 30(9):1887-1895. PubMed ID: 36586758
[TBL] [Abstract][Full Text] [Related]
19. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
Song Y; Lin S; Chen J; Dang J
BMC Cancer; 2023 Oct; 23(1):1043. PubMed ID: 37904083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
